BACKGROUND
Access to methadone treatment can reduce opioid overdose death by up to 60%, but U.S. patient outcomes are suboptimal. Federally-allowed methadone treatment accommodations during the COVID public health emergency were not widely adopted. It is likely that staff-level characteristics such as trauma symptoms influence adoption of treatment innovation.
OBJECTIVE
Methadone Patient Access to Collaborative Treatment (MPACT) is a two-phased project (pilot and field trial) to develop and test a staff-level, multimodal intervention to increase staff adoption of methadone treatment innovation and ultimately improve patient outcomes of treatment retention.
METHODS
A pilot and national trial will measure implementation feasibility, acceptability and effects of the MPACT intervention on treatment practice change, clinic culture, patient retention, and patient Posttraumatic stress symptoms (PTSS). The pilot will be a single-arm 5.5-month pilot study of MPACT conducted in two Arizona methadone treatment clinics (rural and urban) among 100 patients and 22 staff. The national trial will be a 20-month cluster randomized trial conducted among 40 clinics, 800 patients (20 per clinic) and 520 staff (13 per clinic). Data will be gathered by staff and patient survey and patient chart review. The primary study outcome is increased patient methadone treatment retention measured as: 1) time to first treatment interruption from study enrollment, 2) active in treatment at enrollment, day 30, 60, 90, and 120, 3) continuous days in treatment during the study period. Secondary study outcomes include reductions in vicarious trauma (VT) and PTSS among enrolled opioid treatment program staff and PTSS among enrolled patients.
RESULTS
This is a protocol (no results to report)
CONCLUSIONS
The MPACT study will provide a foundation for an evidence-based, staff-level intervention aimed at improving patient retention in methadone treatment. Future studies should examine the individual components of MPACT to determine their differential contributions to the primary outcome of patient methadone treatment retention, and to secondary outcomes of staff and patient reduction in stress symptoms.
CLINICALTRIAL
NCT06513728 (for pilot)
NCT06556602 (for trial)
